122 related articles for article (PubMed ID: 38795961)
21. Testing 2 Alternative Time Trade-Off Methods for Valuation of Children's Health States.
Yang Z; Devlin NJ; Rand K; Luo N
Value Health; 2024 Jan; 27(1):43-50. PubMed ID: 37813195
[TBL] [Abstract][Full Text] [Related]
22. The Egyptian EQ-5D-5L Extensive Pilot Study: Lessons Learned.
Al Shabasy S; Roudijk B; Abbassi M; Finch A; Stolk E; Farid S
Pharmacoeconomics; 2023 Mar; 41(3):329-338. PubMed ID: 36434416
[TBL] [Abstract][Full Text] [Related]
23. The EQ-5D-5L Valuation Study in Egypt.
Al Shabasy S; Abbassi M; Finch A; Roudijk B; Baines D; Farid S
Pharmacoeconomics; 2022 Apr; 40(4):433-447. PubMed ID: 34786590
[TBL] [Abstract][Full Text] [Related]
24. Modifying the Composite Time Trade-Off Method to Improve Its Discriminatory Power.
Jakubczyk M; Lipman SA; Roudijk B; Norman R; Pullenayegum E; Yang Y; Gu NY; Stolk E
Value Health; 2023 Feb; 26(2):280-291. PubMed ID: 36244905
[TBL] [Abstract][Full Text] [Related]
25. EQ-5D-5L Value Set for Slovenia.
Prevolnik Rupel V; Ogorevc M
Pharmacoeconomics; 2023 Nov; 41(11):1515-1524. PubMed ID: 37341959
[TBL] [Abstract][Full Text] [Related]
26. A shortcut to mean-based time tradeoff tariffs for the EQ-5D?
Rand-Hendriksen K; Augestad LA; Dahl FA; Kristiansen IS; Stavem K
Med Decis Making; 2012; 32(4):569-77. PubMed ID: 22247424
[TBL] [Abstract][Full Text] [Related]
27. The EQ-5D-5L Valuation Study in Egypt.
Al Shabasy SA; Abbassi MM; Finch AP; Baines D; Farid SF
Pharmacoeconomics; 2021 May; 39(5):549-561. PubMed ID: 33709283
[TBL] [Abstract][Full Text] [Related]
28. The EQ-5D-5L valuation study in Korea.
Kim SH; Ahn J; Ock M; Shin S; Park J; Luo N; Jo MW
Qual Life Res; 2016 Jul; 25(7):1845-52. PubMed ID: 26961008
[TBL] [Abstract][Full Text] [Related]
29. Valuation of EQ-5D-5L in the Kingdom of Saudi Arabia: A National Representative Study.
Al-Jedai A; Almudaiheem H; Al-Salamah T; Aldosari M; Almutairi AR; Almogbel Y; AlRuthia Y; Althemery AU; Alluhidan M; Roudijk B; Purba FD; Awad N; O'jeil R
Value Health; 2024 May; 27(5):552-561. PubMed ID: 38342365
[TBL] [Abstract][Full Text] [Related]
30. Time and lexicographic preferences in the valuation of EQ-5D-Y with time trade-off methodology.
Lipman SA; Zhang L; Shah KK; Attema AE
Eur J Health Econ; 2023 Mar; 24(2):293-305. PubMed ID: 35596831
[TBL] [Abstract][Full Text] [Related]
31. An EQ-5D-5L value set for Italy using videoconferencing interviews and feasibility of a new mode of administration.
Finch AP; Meregaglia M; Ciani O; Roudijk B; Jommi C
Soc Sci Med; 2022 Jan; 292():114519. PubMed ID: 34736804
[TBL] [Abstract][Full Text] [Related]
32. EQ-5D-Y Value Set for Germany.
Kreimeier S; Mott D; Ludwig K; Greiner W;
Pharmacoeconomics; 2022 Dec; 40(Suppl 2):217-229. PubMed ID: 35604633
[TBL] [Abstract][Full Text] [Related]
33. Censoring Time Trade-off Values at 0 Versus at -1: How Does the Assumption for Worse-Than-Dead Time Trade-off Values Affect the Modeling of EQ-5D-5L Valuation Data?
Yang Z; Rand K; Luo N
Value Health; 2023 May; 26(5):685-693. PubMed ID: 36375679
[TBL] [Abstract][Full Text] [Related]
34. Experience-Based Swedish TTO and VAS Value Sets for EQ-5D-5L Health States.
Burström K; Teni FS; Gerdtham UG; Leidl R; Helgesson G; Rolfson O; Henriksson M
Pharmacoeconomics; 2020 Aug; 38(8):839-856. PubMed ID: 32307663
[TBL] [Abstract][Full Text] [Related]
35. Estimating an EQ-5D-Y-3L Value Set for China.
Yang Z; Jiang J; Wang P; Jin X; Wu J; Fang Y; Feng D; Xi X; Li S; Jing M; Zheng B; Huang W; Luo N
Pharmacoeconomics; 2022 Dec; 40(Suppl 2):147-155. PubMed ID: 36396878
[TBL] [Abstract][Full Text] [Related]
36. A national survey of Iranian general population to estimate a value set for the EQ-5D-5L.
Afshari S; Daroudi R; Goudarzi R; Mahboub-Ahari A; Yaseri M; Sari AA; Ameri H; Bahariniya S; Oliaei-Manesh A; Kalavani K; Zare Z; Hasannezhad E; Mirzaei M; Amiri Z
Qual Life Res; 2023 Jul; 32(7):2079-2087. PubMed ID: 36897530
[TBL] [Abstract][Full Text] [Related]
37. Valuing the EQ Health and Wellbeing Short Using Time Trade-Off and a Discrete Choice Experiment: A Feasibility Study.
Mukuria C; Peasgood T; McDool E; Norman R; Rowen D; Brazier J
Value Health; 2023 Jul; 26(7):1073-1084. PubMed ID: 36805577
[TBL] [Abstract][Full Text] [Related]
38. Toward a Smaller Design for EQ-5D-5L Valuation Studies.
Yang Z; Luo N; Oppe M; Bonsel G; Busschbach J; Stolk E
Value Health; 2019 Nov; 22(11):1295-1302. PubMed ID: 31708067
[TBL] [Abstract][Full Text] [Related]
39. A threshold explanation for the lack of variation in negative composite time trade-off values.
Roudijk B; Donders R; Stalmeier P
Qual Life Res; 2022 Sep; 31(9):2753-2761. PubMed ID: 35622295
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
